GH deficiency during the transition period: Clinical characteristics before and after GH replacement therapy in two different subgroups of patients

Journal of Pediatric Endocrinology and Metabolism

Volumn 25, Issue 1-2, 2012, Pages 97-105

  Fideleff, Hugo L ^a   Jonsson, Björn ^b   Koltowska Häggström, Maria ^c   Boguszewski, Margaret C S ^d   Wilton, Patrick ^e   Boquete, Hugo R ^a  

^a Hospital General De Agudos Teodoro Alvarez   (Argentina)

^b UPPSALA UNIVERSITY   (Sweden)

^c PFIZER INC   (United States)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e Pfizer Endocrine Care   (United States)

Author keywords

Growth hormone deficiency; Growth hormone treatment; Lipids; Metabolic profile; Transition

Indexed keywords

FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; SOMATOMEDIN C; THYROTROPIN; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY HEIGHT; CHILDHOOD ONSET GROWTH HORMONE DEFICIENCY; CHOLESTEROL BLOOD LEVEL; CORTICOTROPIN DEFICIENCY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLICLE STIMUATING HORMONE DEFICIENCY; GROWTH HORMONE DEFICIENCY; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LEAN BODY WEIGHT; LUTEINIZING HORMONE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; SYSTOLIC BLOOD PRESSURE; THYROID STIMULATING HORMONE DEFICIENCY; TRANSITION ONSET GROWTH HORMONE DEFICIENCY; TRIACYLGLYCEROL BLOOD LEVEL; VASOPRESSIN DEFICIENCY; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AGE OF ONSET; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; MALE; QUALITY OF LIFE; REGRESSION ANALYSIS;

EID: 84858247129     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/JPEM.2011.349     Document Type: Article

References (38)

1. Drake WM. Transition of growth hormone-deficient patients from paediatric to adult endocrinologists. In: Abs R, Feldt-Rasmussen U, editors. Growth hormone deficiency in adults-10 years of KIMS, Oxford: Oxford Pharma Genesis Ltd, 2004:209-18.
2. Clayton P, Gleeson H, Monson J, Popovic V, Shalet SM, et al. Growth hormone replacement throughout life: Insights into age-related responses to treatment. GH & IGF Res 2007;17:369-82. (Pubitemid 47342322)
3. Fideleff HL, Boquete HR, Giaccio A, Sobrado P. Medium and long-term outcome of growth hormone therapy in growth hormone deficient adults. Medicina (Buenos Aires) 2006;66:296-302. (Pubitemid 44399097)
4. Hoybye C, Jönsson P, Monson J, Koltowska-Häggström M, Hána V, et al. Impact of primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency. Eur J Endocrinol 2007;157:1-8.
5. Radovick S, DiVall S. Approach to the growth hormone-deficient child during transition to adulthood. J Clin Endocrinol Metab 2007;92:1195-200. (Pubitemid 46556384)
6. Mauras N. GH use in the transition of adolescence to adulthood. Endocr Dev 2010;18:109-25.
7. Carroll PV, Drake WM, Maher KT, Metcalfe K, Shaw NJ, et al. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab 2004;89:3890-5. (Pubitemid 39071490)
8. Vahl N, Juul A, Jorgensen JO, Skakkebaek NE, Christiansen JS. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: A two-year placebo-controlled study. J Clin Endocrinol Metab 2000;85:1874-81. (Pubitemid 32269292)
9. Shalet SM, Shavrikova E, Cromer M, Child CJ, Keller E, et al. Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: A 2 year randomized, controlled, doseranging study. J Clin Endocrinol Metab 2003;88:4124-9. (Pubitemid 37158031)
10. Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, et al. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab 2002;87:3650-5. (Pubitemid 34879507)
11. Mauras N, Pescovitz OH, Allada V, Messig M, Wajnrajch MP, et al. On behalf of the Transition Study Group. Limited effi-cacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: A phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 2005;90:3946-55. (Pubitemid 41065023)
12. Attanasio AF, Lamberts SW, Matranga AM, Birkett MA, Bates PC, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 1997;82:82-8. (Pubitemid 27021275)
13. Fideleff HL, Chervin A, Giaccio A, Sobrado P, Barmat R, et al. Adult growth hormone deficiency: Metabolic alterations and evaluation of different risk groups. Medicina (Buenos Aires) 2004;64:13-9. (Pubitemid 38386602)
14. KIMS: Aetiology of growth hormone deficiency (KIMS classification list). In: Abs R, Feldt-Rasmussen U, editors. Growth hormone deficiency in adults: 10 years of KIMS. Oxford: Oxford Pharma Genesis Ltd, 2004:346-8.
15. Gutierrez LP, Koltowska-Häggström M, Jönsson PJ, Mattsson AF, Svensson D, et al. Registries as a tool in evidence-based medicine: Example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf 2008;17:90-102. (Pubitemid 351187389)
16. Drake WM, Coyte D, Camacho-Hubner C, Jivanji NM, Kaltsas G, et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998;83:3913-9. (Pubitemid 28513572)
17. Johannsson G, Rosen T, Bengtsson B-A Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf) 1997;47:571-81. (Pubitemid 27496332)
18. McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, et al. The QoL-AGHDA: An instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999;8:373-83. (Pubitemid 29369642)
19. Wiren L, Whalley D, McKenna S, Wilhelmsen L. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: Validation of the measure by Rasch analysis. Clin Endocrinol (Oxf) 2000;52:143-52. (Pubitemid 30108259)
20. Koltowska-Häggström M, Mattsson AF, Monson JP, Kind P, Badia X, et al. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life ? Eur J Endocrinol 2006;155:109-19. (Pubitemid 44109071)
21. Lie RF, Schmitz JM, Pierre KJ, Gochman N. Cholesterol oxidase-based determination, by continuous-flow analysis, of total and free cholesterol in serum. Clin Chem 1976;22:1627-30.
22. Fossati P, Prencipe L. Seum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clinical Chemistry 1982;28:2077-80. (Pubitemid 12034053)
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
24. Underwood LE, Murphy MG. Radioimmunoassay of the somatomedins/ insulin-like growth factors. In: Patrano C, Peskar BA, editors. Radioimmunoassay in Basic and Clinical Pharmacology. Berlin: Springer-Verlag, 1987:561-74.
25. Brabant G, von zur Muhlen A, Wuster C, Ranke MB, Kratzsch J, et al. Serum insulin like growth factor I reference values for an automated chemiluminescence immunoassay system: Results from a multicenter study. Horm Res 2003;60:53-60. (Pubitemid 36928670)
26. Riis P. Thirty years of bioethics: The Helsinki Declaration 1964-2003. New Reviews of Bioethics 2003;1:15-25.
27. Karlberg P, Taranger J. The somatic development of children in a Swedish urban community. Acta Paediatr Scan 1976;258:1-148.
28. Satterthwaite FE. An approximative distribution of estimates of variance components. Biometrics 1946;2:110-4.
29. Rosenfeld RG, Nicodemus BC. The transition from adolescence to adult life: Physiology of the " transition " phase and its evolutionary basis. Horm Res 2003;60:74-7. (Pubitemid 37100190)
30. Hochberg Z. Evo-devo of child growth II: Human life history and transition between its phases. Eur J Endocrinol 2009;160:135-41.
31. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. Stanford, California: Stanford University Press, 1959:233.
32. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, et al. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005;152:165-70. (Pubitemid 40309560)
33. Gleeson H, Clayton PE. The transition from childhood to adulthood: Managing dose with growth hormone deficiency, In: Ranke MV, Price DA, Reiter EO, editors. Growth hormone therapy in pediatrics-20 years of KIGS. Basel: Karger, 2007:163-75.
34. Underwood LE, Attie KM, Baptista J. The Genentech Collaborative Study Group. Growth hormone (GH) doseresponse in young adults with childhood-onset GH deficiency: A two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 2003;88:5273-80. (Pubitemid 37452727)
35. Abrams P, Boquete H, Fideleff H, Feldt-Rasmussen U, Jönsson PJ, et al. GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables. Eur J Endocrinol 2008;159:825-32.
36. Kaushal K, Shalet SM. Defining growth hormone status in adults with hypopituitarism. Horm Res 2007;68:185-94. (Pubitemid 350194931)
37. Maiter D, Abs R, Johannsson G, Scanlon M, Jönsson PJ, et al. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: Data from the Pfizer International Metabolic Database. Eur J Endocrinol 2006;155:253-60. (Pubitemid 44269441)
38. Attanasio AF, Howell S, Bates PC, Frewer P, Chipman J, et al. Body composition, IGF-1 and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: A comparison with adult onset GHD patients. J Clin Endocrinol Metab 2002;87:3368-72. (Pubitemid 34822873)